Executive Overview

Fi, a New York-based pet wellness and technology enterprise widely recognized for its smart dog collar infrastructure, has initiated a voluntary recall of select canine dietary supplement products. The action stems from potential contamination with Salmonella, a pathogenic bacterium capable of causing severe gastrointestinal distress and systemic illnesses in both animals and humans. The contamination vector was traced back to an ingredient supplied by a third-party vendor to Fi’s contract manufacturer.

Upon notification of the potential hazard, Fi’s manufacturing partner suspended all production operations associated with the affected product lines. The investigation into the root cause of the raw material breach remains ongoing. In parallel, Fi has activated a direct-to-consumer containment strategy, deploying alerts across its primary retail channels—including its proprietary e-commerce portal, Amazon, and Chewy.com—to mitigate secondary exposure risks.

+-----------------------------------------------------------------------------------+
|                                 RECALL AT A GLANCE                                |
+-----------------------+-----------------------------------------------------------+
| Brand                 | Fi (New York, NY)                                         |
| Hazard                | Potential Salmonella Contamination                        |
| Source of Contaminant | Upstream ingredient supplier to third-party manufacturer  |
| Distribution Channels | Direct-to-Consumer (tryfi.com), Amazon, Chewy.com         |
| Regulatory Oversight  | U.S. Food and Drug Administration (FDA) CVM               |
| Action Required       | Discontinue use immediately, seal, and dispose in trash   |
+-----------------------+-----------------------------------------------------------+

While no fatal incidents have been publicly cited to date, public health officials and veterinary experts caution that Salmonella presents dual-host zoonotic risks. Canine consumption of contaminated chewables or powders can lead to direct clinical disease or render pets asymptomatic shedding vectors. Furthermore, human handlers face significant cross-contamination risks through tactile contact with the supplements, feed bowls, or infected animal waste.

Detailed Chronology

Sourcing and Manufacturing Pipeline

The supply chain event that triggered the recall originated within the raw material procurement network of Fi’s contract manufacturing partner. According to preliminary disclosures, a specific ingredient batch incorporated into two of Fi’s flagship canine supplement formulas failed safety protocols due to potential Salmonella exposure prior to or during secondary processing.

Contract manufacturing in the pet nutraceutical sector frequently relies on complex, multi-tiered supplier networks. When a bulk raw ingredient—such as a protein base, botanical extract, or binding agent—is compromised upstream, it can silently infiltrate downstream production runs across distinct product variants.

Discovery and Internal Production Suspension

Following internal quality assurance screening and notification from the raw material supplier, the manufacturer alerted Fi of the potential cross-contamination event. In response, the manufacturing facility halted all production lines associated with the affected formulations.

[Upstream Supplier] ──> Compromised Raw Ingredient ──> [Contract Manufacturer] 
                                                               │
                                                               ▼
                                                  Batch Production Suspended
                                                               │
                                                               ▼
                                                   Fi Traces Lot Numbers 
                                                               │
                                                               ▼
                                               Voluntary Public Recall Initiated

Fi’s management team coordinated with supply chain operators to isolate distributed inventory from warehouse stocks, tracking the movement of specific lot numbers from manufacturing facilities through distribution networks to end-user fulfillment hubs.

Public Advisory and Regulatory Escalation

Once the specific lot numbers were identified, Fi formally notified the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM). A public recall notice was crafted and issued in alignment with federal safety guidelines.

Fi simultaneously activated its digital communications infrastructure to message direct-to-consumer purchasers, while issuing urgent push notifications and email directives through its retail partners, Amazon and Chewy.com, to ensure comprehensive buyer reach.

Supporting Context & Metrics

Impacted Product Specifications

The scope of this voluntary recall is strictly isolated to specific production lots of two distinct canine health formulations. Consumers and retail partners can verify whether a product in their possession falls within the impacted parameters by reviewing the product name, lot number, net weight, and Universal Product Code (UPC) stamped on the packaging.

No other Fi hardware products, smart collars, or unrelated supplement lot numbers have been implicated in this recall event.

      +--------------------------------------------------------+
      |               PRODUCT IDENTIFICATION GUIDE             |
      +--------------------------------------------------------+
      | Check the bottom or back label of the 180g tub for:    |
      |                                                        |
      |  1. Product  Calming or 8-in-1 Formula           |
      |  2. Lot Number:   26118 (Calming) or 26159 (8-in-1)     |
      |  3. UPC Barcode:  850064800111 or 850055111684         |
      +--------------------------------------------------------+

Zoonotic Risks and Clinical Microbiology of Salmonella

Salmonella is a genus of Gram-negative, rod-shaped bacilli that poses substantial biosecurity risks across species boundaries. Understanding its clinical pathways in both canine hosts and human handlers is essential for assessing exposure dynamics.

                            +--------------------------+
                            |   Salmonella Contaminated |
                            |          Product         |
                            +------------+-------------+
                                         |
                   +---------------------+---------------------+
                   |                                           |
                   ▼                                           ▼
          [Canine Ingestion]                          [Human Handling]
                   |                                           |
         +---------+---------+                       +---------+---------+
         |                   |                       |                   |
         ▼                   ▼                       ▼                   ▼
  Symptomatic Illness   Asymptomatic Carrier    Mild Symptoms    Severe Complications
  - Diarrhea/Blood      - Environmental         - Nausea/Vomiting - Endocarditis
  - Vomiting/Fever        Shedding              - Diarrhea/Fever  - Arterial Infections
  - Abdominal Pain      - Risk to Humans        - Cramping        - Reactive Arthritis

Canine Pathology and Symptomatology

Canines exposed to Salmonella can express a spectrum of clinical manifestations ranging from subclinical carriage to severe systemic illness. Gastrointestinal distress is the primary clinical manifestation.

• Primary Symptoms: Acute lethargy, pyrexia (fever), vomiting, and severe diarrhea, which may present as mucoid or overt blood-streaked stool.
• Secondary Indicators: Significant loss of appetite (anorexia), abdominal distension, and signs of acute abdominal pain upon palpation.
• Subclinical Carriers: Healthy dogs may contract Salmonella without displaying outward symptoms. However, these asymptomatic carriers continue to shed the pathogen in their feces and saliva, creating an invisible vectors of infection within residential environments.

Veterinary professionals advise that if a dog has consumed either of the recalled lots and presents any of these symptoms, owners should seek immediate clinical evaluation.

Human Vulnerability and Transmission Dynamics

Human infection typically occurs via the fecal-oral route, frequently driven by cross-contamination during hand-to-mouth movement after touching contaminated pet chews, unwashed feeding utensils, or exposed surfaces.

• Common Gastrointestinal Symptoms: Infected individuals generally experience nausea, persistent vomiting, severe abdominal cramps, diarrhea (occasionally bloody), and fever within 12 to 72 hours post-exposure.
• Systemic Complications: In rare cases—particularly among pediatric, geriatric, or immunocompromised populations—Salmonella can breach the intestinal mucosa and enter the bloodstream, precipitating extra-intestinal focal infections such as arterial infections, endocarditis, reactive arthritis, generalized myalgia, ocular irritation, and urinary tract infections.

Strict hand hygiene with warm water and soap for a minimum of 20 seconds is recommended immediately following any interaction with pet food, supplements, or animal waste.

E-Commerce Distribution Pathways and Traceability Challenges

The retail architecture for pet nutraceuticals presents distinct trace-and-containment challenges. Because Fi distributed these products via direct-to-consumer (D2C) channels and through third-party platforms like Amazon and Chewy.com, direct contact tracing is partially facilitated by digital purchase records.

                        +----------------------------+
                        |   Fi Fulfillment Center    |
                        +-------------+--------------+
                                      |
         +----------------------------+----------------------------+
         |                            |                            |
         ▼                            ▼                            ▼
  [Direct D2C Platform]      [Amazon Fulfillment]       [Chewy Logistics Network]
         |                            |                            |
         ▼                            ▼                            ▼
  Targeted Email Alert        Automated System Notice      Direct Account Notification
  & Transaction Refund       & Inventory Quarantine       & Order History Advisory

• Direct-to-Consumer (D2C): Purchase records enable Fi to send direct digital notifications to registered customer accounts, allowing rapid communication.
• Third-Party Platforms: Platforms like Amazon and Chewy utilize automated system advisories to flag affected orders, halt active inventory listings, and alert consumers via historical purchasing logs.

However, reverse logistics—ensuring that consumers physically isolate and discard product rather than storing it in pantries—remains a persistent challenge in national food and supplement recalls.

Official Statements and Regulatory Directives

Corporate Response from Fi

In its official communication, Fi emphasized a proactive safety posture, framing the voluntary recall as an imperative preventive measure to safeguard both pets and their owners:

"Fi is promptly notifying all affected customers out of an abundance of caution… The manufacturer has suspended production while it investigates the root cause of the ingredient contamination."

The company has instructed all consumers who purchased items from Lot 26118 or Lot 26159 to halt usage immediately.

                     CONSUMER INSTRUCTION PROTOCOL

       [Step 1]  --->  STOP using the supplement immediately.
       [Step 2]  --->  SEAL the container tightly to prevent spillage.
       [Step 3]  --->  DISPOSE of the product in household trash.
       [Step 4]  --->  SANITIZE all contact surfaces and wash hands.

To assist affected pet owners, Fi established dedicated communication channels active seven days a week:

• Toll-Free Customer Support Line: 1-888-434-3647 (Available daily, 10:00 AM – 8:00 PM Eastern Time)
• Support Email: [email protected]

FDA Regulatory Framework and Adverse Event Reporting

The FDA’s Center for Veterinary Medicine oversees pet food and supplement safety under federal mandates reinforced by the Food Safety Modernization Act (FSMA). The agency monitors voluntary market withdrawals to ensure companies meet statutory obligations regarding public notification and consumer remediation.

The FDA encourages consumers and veterinary medical staff to report adverse events or quality discrepancies associated with these recalled supplements to the Center for Veterinary Medicine’s Adverse Event Reporting program.

• Online Reporting Portal: Reports can be submitted electronically via Form FDA 1932a, accessible through the agency’s reporting hub at www.fda.gov/reportanimalae.
• Official Recall Notice: The FDA’s public advisory regarding this action can be accessed at the FDA Press Release Portal.

Future Outlook and Industry Implications

Quality Assurance Reform in Pet Nutraceuticals

This recall highlights broader challenges facing the pet nutraceutical market, which has seen rapid growth as pet humanization trends drive demand for wellness, joint-health, and calming supplements. Unlike traditional pharmaceuticals, dietary supplements operate in a regulatory environment where quality control relies heavily on supplier auditing and pre-market testing.

                       EVOLVING COMPLIANCE LANDSCAPE

  CURRENT MODEL                           FUTURE ENHANCED MODEL
  +---------------------------------+     +---------------------------------+
  | Upstream Supplier COA           |     | Upstream Supplier COA           |
  | Internal Spot Testing           | ==> | mandatory Multi-Point Testing   |
  | Periodic Audit                  |     | Real-Time DNA/PCR Pathogen Scan |
  | Post-Market Hazard Response     |     | Blockchain Batch Traceability   |
  +---------------------------------+     +---------------------------------+

Industry analysts anticipate that this event will prompt heightened scrutiny regarding how pet wellness companies vet co-packers and raw ingredient suppliers. Key areas of structural reform across the sector are expected to include:

1. Mandatory Multi-Point Pathogen Testing: Implementing mandatory Polymerase Chain Reaction (PCR) screening for Salmonella and Listeria at raw material intake, post-blending, and post-packaging stages.
2. Chain-of-Custody Traceability: Utilizing enhanced batch tracking systems to shorten the window between detecting upstream supplier anomalies and initiating downstream product quarantines.
3. Auditing Standards for Third-Party Co-Packers: Mandating stricter supplier verification protocols and regular third-party facility audits for contract manufacturing partners.

Market Impact on the Digital Pet Wellness Sector

For brands expanding from hardware and technology into consumable wellness products, supply chain integrity is critical to maintaining consumer confidence. Hardware ecosystems rely on brand equity; an issue in a consumable product line can impact consumer trust across the broader brand portfolio.

As Fi works with its manufacturing partner to resolve the investigation and implement enhanced testing protocols, the incident serves as a clear case study for the sector: robust upstream supplier verification and continuous pathogen monitoring remain essential safeguards in the modern pet wellness economy.